Clinical Trial Update: Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy [Phase 3]

View source ↗

Summary

This update covers a Phase 3 trial of EVP-6124 (encenicline), an alpha-7 nicotinic receptor agonist, used as adjunctive pro-cognitive therapy in schizophrenia p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• EVP-6124

Snippet

Sponsor: FORUM Pharmaceuticals Inc | Conditions: Schizophrenia, Impaired Cognition | Phase 3 | Status: COMPLETED